Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 12, Number 6—June 2006

Research

Human Parechovirus Infections in Canada

Yacine Abed*† and Guy Boivin*†Comments to Author 
Author affiliations: *Centre Hospitalier Universitaire de Québec, Quebec City, Quebec, Canada; †Laval University, Quebec City, Quebec, Canada

Main Article

Table

Molecular and virologic characteristics of Canadian HPeV isolates*

Virus HPeV type % nt/aa identities† Neutralization assay‡
Harris 1 NA +
Williamson 2 NA +
Can4541-85 1 76.7/89.9 +
Can-5188-85 1 76.8/89.9 +
Can11750-87 1 76.8/89.9 +
Can11758-87 1 76.8/89.9 +
Can29218-90 1 76.4/89.2 +
Can29192-90 1 75.0/89.6 +
Can40057-93 1 76.8/89.6 +
Can41934-93 1 77.1/89.6 +
Can61165-97 1 77.0/89.9 +
Can82753-01 1 76.5/89.2 +
Can81805-01 1 85.1/97.5 +
Can87376-02 1 76.4/89.6 +
Can87639-02 1 76.4/89.6 +
Can88461-02 1 77.1/89.9 +
Can88770-02 1 76.3/89.2 +
Can85372-02 1 76.5/89.2 +
Can84436-02 1 76.9/89.6 +
Can101909-04 1 76.6/89.6 +
Can102318-04 1 76.6/89.6 +
Can100121-04 1 77.0/89.2 +
Can82047-01 2 81.1/96.4 +
Can95219-03 2 67.8/72.5
Can95224-03 2 67.8/72.5
Can81235-01 3 95.3/96.1
Can81554-01 3 95.0/95.7
Can82853-01 3 95.5/96.4
Can99190-04 3 95.0/96.1
Can97858-04 3 95.0/96.4

*HPeV, human parechovirus; nt, nucleotide; aa, amino acid; NA, not applicable.
†% identities were calculated by comparison with Harris (accession no. S45208), Williamson (accession no. AJ005695) and A308/99 (accession no. AB084913) reference strains for HPeV-1, -2 and -3 isolates, respectively.
‡Neutralization assays were performed by using specific HPeV-1 and -2 (formerly echovirus 22 and 23, respectively) antisera (MA Bioproducts, Walkersville, MD, USA).

Main Article

TOP